Demonstrating a Fully Continuous Bioprocess

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology, Trends in Manufacturing, May 2022, Volume 2022 eBook, Issue 2
Pages: 30–34

Flexible and efficient methods are needed for biopharmaceutical manufacturing.

Continuous manufacturing for biopharmaceutical drugs offers the potential for similar advantages to those that can be obtained by continuous processing of small-molecule drugs, including higher efficiency and flexibility of scale. At Sweden’s AdBIOPRO (the Competence Centre for Advanced BioProduction by Continuous Processing), researchers from Lund University and KTH Royal Institute of Technology aim to advance understanding of continuous bioprocessing to support industry efforts.

To this end, AdBIOPRO researchers conducted a scale-up project at the Testa Center in Uppsala, Sweden, which is a pilot-scale test center that is an initiative between the Swedish government and life sciences company Cytiva. The group demonstrated that it is possible to run a large-scale, automated continuous bioprocess in which a cell culture operated in perfusion mode directly and automatically connects to a continuous purification process, says Veronique Chotteau, professor at KTH Royal Institute of Technology and head of AdBIOPRO. Pharmaceutical Technology spoke with Chotteau about the group’s proof-of-concept work and the key components that are needed to run a fully continuous bioprocess that connects both upstream and downstream processing in one workflow.


Read this article in the Trends in Manufacturing ebook.

About the author

Jennifer Markarian was previously manufacturing editor and is currently manufacturing reporter for Pharmaceutical Technology.

Article details

Pharmaceutical Technology
eBook: Trends in Manufacturing
May 2022
Pages: 30–34


When referring to this article, please cite it as J. Markarian, " Demonstrating a Fully Continuous Bioprocess," Pharmaceutical Technology's Trends in Manufacturing eBook (May 2022).